TRCT
BBOT

Tower Research Capital (TRC)’s BridgeBio Oncology BBOT Stock Holding History

Tower Research Capital (TRC)’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Buy
+1,696
New +$14.2K ﹤0.01% 3884
2025
Q1 		– Sell
-1
Closed -$10 – 5877
2024
Q4 		$10 Buy
+1
New +$11 ﹤0.01% 5623

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tower Research Capital (TRC)'s BBOT Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in BridgeBio Oncology (BBOT) in Q2 2026: 1,696 shares worth $12.9K. The stake represents ﹤0.01% of the portfolio and ranks #3884 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in BBOT as recently as Q4 2024.

Tower Research Capital (TRC) first reported a position in BBOT in Q4 2024 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Tower Research Capital (TRC) held 1,696 shares of BridgeBio Oncology worth $12.9K as of Q2 2026.
  • BridgeBio Oncology was a new Tower Research Capital (TRC) position in Q2 2026.
  • BridgeBio Oncology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3884 holding.
  • Tower Research Capital (TRC) first reported a position in BridgeBio Oncology in Q4 2024 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.